CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the preliminary safety, efficacy and PK
characteristics of cend-1 in patients with advanced metastatic pancreatic ductal
adenocarcinoma (Chinese population).